Rani Therapeutics Holdings, Inc. (RANI)

Market Cap	89.40M +366.6%
Revenue (ttm)	3.17M +164.1%
Net Income	-29.44M
EPS	-0.29
Shares Out	99.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,041,352
Open	0.9499
Previous Close	0.9508
Day's Range	0.8900 - 0.9555
52-Week Range	0.3870 - 3.8700
Beta	0.76
Analysts	Strong Buy
Price Target	7.50 (+737.33%)
Earnings Date	May 15, 2026

About RANI

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in prec...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 71
• Stock Exchange: NASDAQ
• Ticker Symbol: RANI
• Website: https://www.ranitherapeutics.com

Financial Performance

In 2025, RANI's revenue was $1.63 million, an increase of 58.85% compared to the previous year's $1.03 million. Losses were -$29.67 million, -1.15% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for RANI stock is "Strong Buy." The 12-month stock price target is $7.5, which is an increase of 737.33% from the latest price.

Price Target

$7.5

(737.33% upside)

Analyst Consensus: Strong Buy